company profile

company profile Factory Tour Quality Control

Home >

Beijing Anrate Biotechnology Co., Ltd. company profile

Beijing Anrate Biotechnology Co., Ltd.

About Us

company profile

Factory Tour

Quality Control

+86-010-63723986

sales@bjanrate.cn

Contact Now

Company Details

Main Market:

North America , South America , Western Europe , Eastern Europe , Eastern Asia , Southeast Asia , Middle East , Africa , Oceania , Worldwide

Business Type:

Distributor/Wholesaler , Agent

Brands:

Anrate

No. of Employees

19~49

Annual Sales

99999-9999999

Year Established

2021

Export p.c

80% - 90%

Customers Served

Introduction

Beijing Anrate Biotechnology Co., Ltd. is a wholly-owned subsidiary of Tonghua Anrate Biopharmaceutical Co., Ltd. It specializes in the global marketing and sales of high-end recombinant protein products for biopharmaceutical and life science cell culture applications. Backed by the parent company’s mature GMP production system, original Pichia pastoris expression platform and years of professional R&D experience, we mainly supply cell culture grade recombinant human albumin and recombinant human transferrin. All products are animal-free with stable batch consistency and high safety performance. Widely applied in vaccine development, cell therapy, antibody drugs and serum-free medium formulation, we provide reliable, compliant and high-quality domestic recombinant protein solutions for global biopharmaceutical customers.

Service

As a wholly-owned subsidiary of Tonghua Anrate Biopharmaceutical Co., Ltd., Beijing Anrate Biotechnology drives the global marketing and distribution of high-quality cell culture media proteins, including recombinant human albumin and recombinant human transferrin. Our core portfolio features cell culture grade products tailored for biopharma and life science applications.

History

Development History and Corporate Advantages of Beijing Anrate Biotechnology

I. Birth Background: Parent Company's Technical Accumulation (2012-2020)

The establishment of Beijing Anrate stems from the long-term technical accumulation and strategic layout of its parent company, Tonghua Anrate Biopharmaceutical Co., Ltd.:

2012: Shanghai Anrate Biomedical Technology Co., Ltd. undertook the national "12th Five-Year Plan" Major New Drug Creation Project, launching the research and development of recombinant human albumin technology.

August 7, 2014: Shanghai Anrate jointly established Tonghua Anrate Biopharmaceutical Co., Ltd. with Dongbao Industrial Group, focusing on the industrialization and development of recombinant human albumin injection, a national Class I new drug.

2017-2018: Tonghua Anrate completed the pre-clinical research of recombinant human albumin injection, built the world’s first 100-kiloliter fermentation and purification CMC production line, and obtained the Drug Production License.

2019-2020: Tonghua Anrate advanced the clinical trials of recombinant human albumin injection and fully implemented the GMP management system in production, laying a solid foundation for commercial layout.

II. Official Establishment: Focus on Cell Culture Protein Market (2021)

April 7, 2021: Beijing Anrate Biotechnology Co., Ltd. was officially registered in Fengtai District Science City, Beijing. The legal representative is Xiang Wei, with a registered capital of 10 million RMB.

Core Positioning: As the marketing and market expansion platform of Tonghua Anrate, the company focuses on the global promotion and sales of cell culture medium protein products such as recombinant human albumin and recombinant human transferrin.

Strategic Significance: Relying the parent company’s world-leading recombinant protein production technology, it fills the domestic market gap of animal-free proteins for cell culture, and serves cutting-edge fields including biopharmaceuticals, vaccine research and development, and cell therapy.

III. Development History: Business Expansion and Product Upgrade (2021-2026)

Time	Key Milestones
2021	Established a professional sales team, built a national sales network, and launched cell culture grade recombinant human albumin (ART103L).
2022	Expanded overseas markets, established cooperation with multiple international biological reagent distributors, and products entered European and American laboratories.
2023	Launched the recombinant human transferrin product line, improving the overall solution for cell culture medium proteins.
2024	The parent company’s recombinant human albumin injection was successfully launched globally for the first time, providing strong technical endorsement for Beijing Anrate’s products.
2025-2026	Further expand market coverage, build an integrated "technology + sales" service system, and grow into a core supplier of cell culture proteins in China.

IV. Core Advantages and Market Positioning

Technical Origin: It shares Tonghua Anrate’s world-first 100-kiloliter Pichia pastoris expression system and online liquid preparation chromatography technology, ensuring products with high purity, zero animal-derived components and stable batch consistency.

Product Features: Specializes in cell culture grade recombinant human albumin and recombinant human transferrin, meeting the strict requirements of the biopharmaceutical industry for serum-free culture media.

Market Positioning: Committed to providing safe, reliable and scalable cell culture protein raw materials for biopharmaceutical enterprises, vaccine R&D institutions and cell therapy companies, boosting the high-quality development of the biomedical industry.

V. Parent Company Connection and Industrial Synergy

Beijing Anrate and Tonghua Anrate form a full-industry-chain synergy covering R&D, production and sales:

Tonghua Anrate is responsible for core technology research and development, pharmaceutical-grade product production and quality control.

Beijing Anrate focuses on market promotion, customer service and technical support for cell culture grade products.

Both parties share unified quality standards and technical platforms to ensure the consistency and reliability of products from R&D to practical application.

Our Team

Beijing Anrate brings together senior professionals in recombinant protein technology and biomedicine, forming an elite team deeply engaged in the cutting-edge tracks of biopharmaceuticals, cell therapy, regenerative medicine, and precision medicine. With years of experience in the field of animal-free biological raw materials, our core members precisely focus on core application scenarios including serum-free medium development, NK cell and stem cell culture, excipients for vaccines and antibody drugs, as well as cell cryopreservation protection, and are well versed in industry standards and core demands of global customers.

Backed by the world-leading recombinant protein R&D and production capabilities of parent company Tonghua Anrate, with an annual production capacity of 50 tons and product purity exceeding 99.999985%, our team has built a full-chain professional service system covering market promotion, technical consultation, customer service and after-sales support. Adhering to the rigorous, pragmatic and customer-oriented philosophy, we precisely serve global biopharmaceutical enterprises, vaccine R&D institutions, cell therapy companies and high-end scientific research laboratories, efficiently meeting customer needs for raw material procurement, process adaptation and technical customization.

Keeping pace with industry frontiers, the team continuously explores application scenarios and optimizes service processes. With solid technical expertise and efficient response capability, we provide stable, compliant and customized solutions for recombinant human albumin and recombinant human transferrin, empowering the high-quality innovative development of the global biomedical industry.

Send your inquiry directly to us